Vigabatrin-induced peripheral visual field defects in patients with refractory partial epilepsy.
OBJECTIVE
Vigabatrin can cause retinopathy, resulting in bilateral visual field constriction. Previous analyses of results from a prospective, observational study assessing vigabatrin-induced visual field constriction (described below) employed a partially subjective interpretation of static perimetery. To affirm these previous findings through more objective, quantitative methodology, we now report data from a subset analysis of refractory partial epilepsy patients in the study who underwent Goldmann kinetic perimetry.


METHODS
Patients aged ≥ 8 years with refractory partial seizures were enrolled and grouped: those receiving vigabatrin for ≥ 6 months (Group I); those who had received vigabatrin for ≥ 6 months and then had discontinued for ≥ 6 months (Group II); and those naïve to vigabatrin (Group III). Patients underwent static or kinetic perimetry, or both, every 4-6 months for ≤ 3 years. For kinetic perimetry, the temporal and nasal visual fields were measured along the horizontal meridian with the largest (V4e, IV4e) and smallest (I2e, I1e) isopters, respectively.


RESULTS
Of 735 patients enrolled, 341 had Goldmann perimetry data. Of these, 258 received vigabatrin. Sixteen percent of vigabatrin-exposed patients had moderate visual field defects (30-60° retained temporal vision), and 3% had severe defects (< 30° retained temporal vision). Visual function questionnaire results indicated a weak correlation between visual field constriction severity and visual symptoms.


CONCLUSIONS
These results affirm both an analysis of the same study based primarily on static perimetry and findings from cross-sectional studies. The present analysis verifies that visual field constriction, when it occurs, is most often mild or moderate and is not associated with symptoms of abnormal visual function. The clinical decision to prescribe vigabatrin should be based on a benefit-risk analysis for each individual patient.
Wills Eye Institute, Neuro-Ophthalmology Service, Thomas Jefferson University Medical College, Philadelphia, PA 19107, USA. rcs220@comcast.net
Robert C
RC
Sergott
Richard M
RM
Bittman
Erin M
EM
Christen
Stephen M
SM
Sagar
D000927:Anticonvulsants / Q000009:adverse effects*; D002648:Child; D004828:Epilepsies, Partial / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007391:International Cooperation; D008297:Male; D011795:Surveys and Questionnaires; D020888:Vigabatrin / Q000009:adverse effects*; D014786:Vision Disorders / Q000139:chemically induced* / Q000175:diagnosis; D058609:Visual Field Tests / Q000379:methods; D014794:Visual Fields / Q000187:drug effects*
D000927:Anticonvulsants; D020888:Vigabatrin